---
title: "Processa Pharmaceuticals, Inc. (PCSA.US)"
type: "quote"
locale: "en"
url: "https://longbridge.com/en/quote/PCSA.US.md"
symbol: "PCSA.US"
name: "Processa Pharmaceuticals, Inc."
industry: "制药"
---

# Processa Pharmaceuticals, Inc. (PCSA.US)

| Item | Detail |
|------|--------|
| Industry | 制药 |
| Location | 美股市场 |
| Website | [www.processapharmaceuticals.com](https://www.processapharmaceuticals.com) |

## Company Profile

Processa Pharmaceuticals, Inc.是一家临床阶段的生物制药公司，开发化疗药物以提高癌症治疗的安全性和有效性。其药物是现有 FDA 批准的肿瘤药物的改良版，旨在改变药物的代谢和/或分布，同时保持现有的杀死癌细胞的机制。该公司的产品线包括三种化疗药物，分别是：吉西他滨（Gemcitabine），PCS3117 已完成针对胰腺、胆道、肺、卵巢、乳腺及其他癌症的 2a 期临床试验；卡培他滨（Capecitabine），PCS6422 与卡培他滨的组合，目前正在进行针对转移性结直肠、胃肠道、乳腺、胰腺及其他癌症的 2 期临床试验；以及伊立替康（Irinotecan），PCS11...

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -0.37 | 82/257 | - | - | - |
| PB | 0.82 | 36/257 | 2.29 | 1.40 | 0.78 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-02-09T05:00:00.000Z

Total Analysts: **1**

| Rating | Count | Percentage |
|--------|-------|-----------|
| Buy | 1 | 100% |
| Overweight | 0 | 0% |
| Hold | 0 | 0% |
| Underweight | 0 | 0% |
| Sell | 0 | 0% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 2.10 |
| Highest Target | 25.00 |
| Lowest Target | 25.00 |

## References

- [Company Overview](https://longbridge.com/en/quote/PCSA.US/overview.md) - Shareholders, executives, business segments
- [Financials](https://longbridge.com/en/quote/PCSA.US/norm.md) - Income statement, balance sheet, cash flow, distribution plan
- [Topics & Discussions](https://longbridge.com/en/quote/PCSA.US/topics.md) - Community topics and discussions

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.